Klaus Schmierer, MB BS, PhD, FRCP, Queen Mary University of London & The Royal London Hospital of Barts Health NHS Trust, London, UK, explains the AttackMS study, which aims to reduce the delay from diagnosis to treatment of individuals with multiple sclerosis (MS). The rationale for this goal is data showing the positive long-term outcomes for patients receiving early and aggressive treatment. In AttackMS, the feasibility of intervention with natalizumab within 14 days of symptom onset will be investigated, as well as if this approach can facilitate brain lesion repair. The trial will enroll patients aged under 45 who are within 14 days of symptom presentation and have at least two MRI lesions. The question remains as to how best to quickly diagnose patients in an acute scenario. This interview took place at the MS Frontiers 2022 congress in Swansea, UK.
KS has received research support from Biogen, the healthcare business of Merck KGaA (Darmstadt, Germany), and Novartis; speaking honoraria from, and/or served in an advisory role for, Amgen- Gensenta, Biogen, EMD Serono, the healthcare business of Merck KGaA (Darmstadt, Germany), Novartis, Roche, Sanofi, and Teva; and remuneration for teaching activities from AcadeMe, Medscape, and the Neurology Academy.